Right on the heels of $150M raise, Ascentage files the latest in a rush of HKEX biotech IPOs — but is the market too jittery?
When I spoke to Ascentage CEO Dajun Yang last month about their $150 million raise, he dodged my question about the prospects for an IPO. As it turned out, we didn’t have to wait long for the answer.
The fast-growing biotech posted their application on the Hong Kong stock exchange Monday, marking the 10th biopharma company to line up their IPO pitch — all debuts except for BeiGene — since the city opened up to pre-revenue biotechs in April.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.